-
1.发明授权公开(公告)号：US11857714B2
公开(公告)日：2024-01-02
申请号：US18100023
申请日：2023-01-23
Applicant: Fenwal, Inc.
Inventor： Zahra R Ali , Lan T. Nguyen
CPC classification number: A61M1/3607 , A61M1/0209 , A61M1/361 , A61M1/3643 , A61M1/3672 , A61M1/3683 , A61M1/3693 , A61M1/3696 , A61M1/38 , A61M2202/0092 , A61M2202/0407 , A61M2202/0413 , A61M2202/0415 , A61M2202/0429 , A61M2202/0439 , A61M2202/0443 , A61M2205/3386 , A61M2205/50 , A61M2230/005 , A61M2230/207
Abstract: Described is a method for controlling fluid volume balance. A controller is configured with a first set of inputs comprising a hematocrit, a total blood volume, and an ACD ratio. A maximum extracorporeal RBC amount during the procedure is estimated based on the first set of inputs. A fluid circuit is primed with a priming fluid. Whole blood is drawn from a blood source and separated into a RBC component, a target cell component, and a plasma component. The target cell component is directed to a product container. The product container comprising the target cell component is treated. A treated target cell component, a portion of the RBC component remaining in the fluid circuit, and/or a portion of the plasma component remaining in the fluid circuit are returned to the blood source. A first response action is provided if the maximum extracorporeal RBC amount estimated is above a programmed limit.
-
公开(公告)号：US20170197023A1
公开(公告)日：2017-07-13
申请号：US15390549
申请日：2016-12-26
Applicant: Fenwal, Inc.
Inventor： Katherine N. Radwanski , Lan T. Nguyen , Jonathan W. Prendergast
CPC classification number: A61M1/3681 , A61M1/0209 , A61M1/262 , A61M1/3472 , A61M1/3496 , A61M1/3679 , A61M1/3693 , A61M2202/0443 , A61M2205/051 , A61M2205/331 , B04B3/00
Abstract: A method of collecting mononuclear cells, comprising separating whole blood into plasma and cellular components, combining the cellular components with plasma replacement fluid to form a first mixture, and separating the first mixture into mononuclear cells and at least one component.
-
3.发明公开公开(公告)号：US20230149615A1
公开(公告)日：2023-05-18
申请号：US18100023
申请日：2023-01-23
Applicant: Fenwal, Inc.
Inventor： Zahra R. Ali , Lan T. Nguyen
CPC classification number: A61M1/3607 , A61M1/38 , A61M1/0209 , A61M1/361 , A61M1/3643 , A61M1/3672 , A61M1/3683 , A61M1/3693 , A61M1/3696 , A61M2202/0092 , A61M2202/0407 , A61M2202/0413 , A61M2202/0415 , A61M2202/0429 , A61M2202/0439 , A61M2202/0443 , A61M2205/50 , A61M2205/3386 , A61M2230/005 , A61M2230/207
Abstract: Described is a method for controlling fluid volume balance. A controller is configured with a first set of inputs comprising a hematocrit, a total blood volume, and an ACD ratio. A maximum extracorporeal RBC amount during the procedure is estimated based on the first set of inputs. A fluid circuit is primed with a priming fluid. Whole blood is drawn from a blood source and separated into a RBC component, a target cell component, and a plasma component. The target cell component is directed to a product container. The product container comprising the target cell component is treated. A treated target cell component, a portion of the RBC component remaining in the fluid circuit, and/or a portion of the plasma component remaining in the fluid circuit are returned to the blood source. A first response action is provided if the maximum extracorporeal RBC amount estimated is above a programmed limit.
-
4.发明申请公开(公告)号：US20170266362A1
公开(公告)日：2017-09-21
申请号：US15505724
申请日：2015-08-25
Applicant: 3M INNOVATIVE PROPERTIES COMPANY
Inventor： Bodo von Harten , Detlef Krieter , Horst-Dieter Lemke
IPC: A61M1/36
CPC classification number: A61M1/3633 , A61M1/34 , A61M1/3406 , A61M1/341 , A61M1/3472 , A61M1/3679 , A61M1/3693 , A61M2202/0014 , A61M2202/0441 , A61M2202/0443 , A61M2202/0445 , B01D15/26 , B01D39/14 , B01D61/00 , B01D63/02 , B01D69/02 , B01D2325/20 , B01J20/28
Abstract: A blood treatment system comprising at least one first device and at least one second device, wherein the first device is a membrane filter for the removal of toxic mediators from blood and the second device is suitable for the removal of granulocytes and monocytes from blood. The first device has a first blood flow path a first blood flow path for conducting blood through and the second device has a second blood flow path. The first and second devices are serially connected in succession in such a way that the first blood flow path is in fluid communication with the second blood flow path.The membrane has an interior filter space in its housing and a semipermeable membrane arranged in the interior filter space, which membrane divides the interior filter space into a retentate chamber and permeate chamber. The housing has a blood inlet device and a blood outlet device that are in fluid communication with the retentate chamber, as well as a permeate outlet for diverting permeate from the permeate chamber. The blood inlet device, the retentate chamber and the blood outlet device form the first blood flow path. The membrane filter has a separation characteristic such that the sieve coefficient for albumin, SKAlb, is within the range from 0.015 to 0.35.
-
公开(公告)号：US20160175514A1
公开(公告)日：2016-06-23
申请号：US14577124
申请日：2014-12-19
Applicant: Fenwal, Inc.
Inventor： Melissa A. Thill , Samantha M. Planas , Amit J. Patel , Courtney Moore , William H. Cork
CPC classification number: A61M1/38 , A61M1/265 , A61M1/3406 , A61M1/3496 , A61M1/3672 , A61M2202/0415 , A61M2202/0443 , A61M2205/18 , A61M2205/331 , A61M2205/3327 , A61M2205/702 , A61M2205/75 , A61M2230/20 , G01N21/59 , G01N33/491 , G01N2201/12
Abstract: A system is provided for separating a plasma-containing fluid into separated plasma and a concentrated fluid. The system cooperates with a fluid flow circuit including a fluid separation chamber and a plasma outlet line associated therewith for removing separated plasma from the fluid separation chamber. The system includes an optical sensor assembly to monitor the contents of the plasma outlet line and produce an output indicative of the concentration of free plasma hemoglobin in the plasma outlet line. A controller of the system calculates the amount of free plasma hemoglobin in at least a portion of the concentrated fluid based at least in part on the output of the optical sensor assembly. The controller may periodically calibrate the optical sensor assembly by determining an instrument-specific correlation between optic output and free hemoglobin concentration and comparing it to experimentally determined data to ensure continued reliability of the optical sensor assembly.
Abstract translation: 提供了一种用于将含血浆的流体分离成分离的等离子体和浓缩流体的系统。 该系统与包括流体分离室和与其相关联的等离子体出口管线的流体流动回路相配合，用于从流体分离室去除分离的等离子体。 该系统包括光学传感器组件，用于监测等离子体出口管线的内容物，并产生指示血浆出口管线中游离血浆血红蛋白浓度的输出。 该系统的控制器至少部分地基于光学传感器组件的输出来计算至少一部分浓缩流体中的游离血浆血红蛋白的量。 控制器可以通过确定光学输出和游离血红蛋白浓度之间的仪器特异性相关性来定期校准光学传感器组件，并将其与实验确定的数据进行比较，以确保光学传感器组件的持续可靠性。
-
Patent Agency Ranking
公开(公告)号：US09833557B2
公开(公告)日：2017-12-05
申请号：US14577124
申请日：2014-12-19
Applicant: Fenwal, Inc.
Inventor： Melissa A. Thill , Samantha M. Planas , Amit J. Patel , Courtney Moore , William H. Cork
CPC classification number: A61M1/38 , A61M1/265 , A61M1/3406 , A61M1/3496 , A61M1/3672 , A61M2202/0415 , A61M2202/0443 , A61M2205/18 , A61M2205/331 , A61M2205/3327 , A61M2205/702 , A61M2205/75 , A61M2230/20 , G01N21/59 , G01N33/491 , G01N2201/12
Abstract: A system is provided for separating a plasma-containing fluid into separated plasma and a concentrated fluid. The system cooperates with a fluid flow circuit including a fluid separation chamber and a plasma outlet line associated therewith for removing separated plasma from the fluid separation chamber. The system includes an optical sensor assembly to monitor the contents of the plasma outlet line and produce an output indicative of the concentration of free plasma hemoglobin in the plasma outlet line. A controller of the system calculates the amount of free plasma hemoglobin in at least a portion of the concentrated fluid based at least in part on the output of the optical sensor assembly. The controller may periodically calibrate the optical sensor assembly by determining an instrument-specific correlation between optic output and free hemoglobin concentration and comparing it to experimentally determined data to ensure continued reliability of the optical sensor assembly.
-
公开(公告)号：US20150320938A1
公开(公告)日：2015-11-12
申请号：US14271084
申请日：2014-05-06
Applicant: Biomet Biologics, LLC
Inventor： William KING , Jennifer E. Woodell-May
CPC classification number: A61M5/31596 , A61B10/025 , A61B10/0283 , A61B2010/0258 , A61M5/3145 , A61M5/31511 , A61M2202/0413 , A61M2202/0443 , A61M2202/062 , A61M2202/09 , A61M2202/10
Abstract: A device for processing a biological material is disclosed. The device includes a syringe barrel comprising beads, a filter positioned at a close end of the barrel, a plunger insertable into the barrel through an open end, and a needle. The plunger includes a paddle assembly that is configured to mix a biological material with the beads after the biological material has been harvested from a patient.
Abstract translation: 公开了一种用于处理生物材料的装置。 该装置包括注射器筒，其包括珠，位于筒的近端的过滤器，通过开口端插入到筒中的柱塞和针。 柱塞包括桨组件，其被配置成在从患者收获生物材料之后将生物材料与珠混合。
-
8.发明授权
公开(公告)号：US4878895A
公开(公告)日：1989-11-07
申请号：US248744
申请日：1988-09-26
Applicant: Phillip H. Klesius , Debra A. Cross
Inventor： Phillip H. Klesius , Debra A. Cross
CPC classification number: A61B10/02 , A61M1/1678 , A61M1/3679 , A61M2202/0443 , A61M39/0208
Abstract: The instant invention pertains to improvements in processes and apparatus for stimulating, collecting, and optionally modifying, macrophages from the peritoneal cavity of a vertebrate.
Abstract translation: 本发明涉及用于从脊椎动物的腹膜腔刺激，收集和任选地修饰巨噬细胞的方法和装置的改进。
-
公开(公告)号：US09974899B2
公开(公告)日：2018-05-22
申请号：US14758328
申请日：2013-02-06
Applicant: Fenwal, Inc.
Inventor： Katherine Radwanski , Min Kyungyoon
IPC: A61M1/36
CPC classification number: A61M1/3681 , A61M1/3683 , A61M1/3692 , A61M1/3693 , A61M1/3696 , A61M2202/0407 , A61M2202/0443 , A61M2205/053 , A61M2205/33
Abstract: A method provided for determining a range for the amount of light-energy attenuating material that may be present in a suspension containing target cells (such as MNCs), light-energy attenuating matter (such as RBCs and plasma), and a light-energy activatable compound (such as psoralen) so that a desired therapeutic effect (such as the percentage of MNCs in which apoptosis occurs) is obtained when the suspension is subjected to a known amount of light energy. In a related aspect, a method is provided for preparing a suspension containing target cells, light-energy attenuating matter, and a light-energy activatable compound so that a desired therapeutic effect is obtained when the suspension is subjected to a known amount of light energy.
-
公开(公告)号：US20180078699A1
公开(公告)日：2018-03-22
申请号：US15693799
申请日：2017-09-01
Applicant: Fenwal, Inc.
Inventor： Jonathan W. Prendergast , Lan T. Nguyen , Katherine N. Radwanski
CPC classification number: A61M1/3693 , A61M1/0209 , A61M1/3496 , A61M1/361 , A61M1/3672 , A61M1/38 , A61M1/385 , A61M2202/0427 , A61M2202/0439 , A61M2202/0443 , B01D63/16
Abstract: A method of collecting mononuclear cells, comprising separating whole blood into cellular components and platelets suspended in plasma, separating the platelets suspended in plasma into platelet concentrate and platelet-poor plasma, combining the cellular components with the platelet-poor plasma to form a first mixture, and separating the first mixture into mononuclear cells and at least one component.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.012 seconds)
